Adverse events

Study	Description	Liraglutide 1.8 mg daily	Glimepiride 4 mg daily
L ‐ LEAD 2 Nauck 2009	withdrawal due to adverse events	12%	3%
L ‐ LEAD 2 Nauck 2009	withdrawal due to nausea/vomiting/diarrhoea	8%	0
L ‐ LEAD 2 Nauck 2009	no significant differences across groups for: physical examination findings, laboratory analyses, ECG, ophthalmoscopy
L ‐ LEAD 2 Nauck 2009	any GI event	44%	17%
L ‐ LEAD 2 Nauck 2009	nausea	19%	3 to 4%
L ‐ LEAD 2 Nauck 2009	vomiting	5 to 7%	1%
L ‐ LEAD 2 Nauck 2009	diarrhoea	15%	4%
L ‐ LEAD 2 Nauck 2009	serious adverse events: 2 deaths unrelated to liraglutide treatment; 1 participant each in 1.2 mg liraglutide group and in glimepiride group withdrawn due to acute pancreatitis
L ‐ LEAD 2 Nauck 2009	injection site reactions	NR	NR
L ‐ LEAD 2 Nauck 2009	anti‐liraglutide antibodies	NR	NR
L ‐ Yang 2010	withdrawal due to adverse events	12.9%	1.3%
L ‐ Yang 2010	serious adverse events	1.7 to 3.4%	1.7 to 3.4%
L ‐ Yang 2010	pancreatitis	none	none
L ‐ Yang 2010	deaths	none	none
L ‐ Yang 2010	anti‐liraglutide antibodies	n = 8 from all liraglutide groups	‐
L ‐ Yang 2010
L ‐ Yang 2010
L ‐ Yang 2010
L ‐ Yang 2010
L ‐ Yang 2010